Sell-Side Rating Pressure and a Flawed Performance Composite
An analyst at a boutique broker covers MedTech Devices. MedTech is also an investment-banking client, and the IB managing director tells the analyst that “the client is furious about your hold rating; a $40 million follow-on mandate is at stake, and your bonus is tied to firm revenue.” The analyst's DCF values MedTech at $28 per share versus a $34 market price, but a new product could add $3 per share if approved. A supplier's filing discloses a safety warning about a component used in MedTech's flagship device; the analyst's draft report omits it because the supplier is not a covered company. Separately, the firm markets a “MedTech Select” composite with an 18.2% gross return. The composite includes only the three best-performing accounts, excludes a terminated account that underperformed, and backfills a new account from an earlier period. The firm claims compliance with GIPS but has no policies for composite inclusion or error correction.
1. Identify the ethical and professional standards issues in the rating pressure and the draft report. What should the analyst do?
Read the worked answer
The IB pressure implicates Independence and Objectivity. An analyst must not let investment-banking revenue, compensation, or client relationships influence a recommendation. The bonus tied to firm revenue creates a conflict that must be disclosed and, ideally, removed. The analyst should not change the rating because of the mandate threat. The draft report omitting the supplier's safety warning implicates Misrepresentation and Diligence: a reasonable basis requires investigating material information, especially a safety issue for a medical device. The fact that the supplier is not covered does not make the information immaterial. The report also risks violating the duty to clients if it presents a one-sided thesis.
Actions: document the IB conversation and escalate to compliance or the research oversight committee immediately. Publish the hold rating with the DCF and the safety-warning risk disclosed; if the information cannot be verified, disclose the uncertainty rather than omit it. Do not share the draft with IB before publication beyond normal compliance review. Ensure the analyst's compensation is not tied to specific IB mandates. If the firm cannot protect research independence, the analyst should consider whether to continue covering the name and should seek compliance's written guidance. The standard is not “can I defend the rating?” but “would a client see the analysis as independent and complete?”
2. Evaluate the “MedTech Select” composite against GIPS requirements. Identify the specific violations and the corrective actions.
Read the worked answer
The composite violates several GIPS requirements. Composites must include all actual, fee-paying, discretionary portfolios that meet the composite definition; selecting only the three best accounts is cherry-picking and misrepresents performance. Terminated portfolios must be included in the composite's history up to the last full measurement period they were managed; excluding the terminated underperformer is a violation. Backfilling a new account into an earlier period is not allowed unless the account actually met the composite definition and was managed in that period; linking simulated or backtested performance to actual performance is prohibited. The firm also cannot claim GIPS compliance without policies for composite construction, inclusion, and error correction. The 18.2% gross return must be accompanied by net-of-fees disclosure and cannot be presented as the only result.
Corrective actions: restate the composite to include all eligible portfolios, including the terminated account for its actual period, and remove the backfilled account. Recalculate gross and net returns with the firm's actual fee schedule. Adopt written policies on composite definitions, discretion, significant cash flows, and error correction. Disclose the correction to prospective clients and remove the GIPS compliance claim until verification and policies are in place. The Firm should also review whether marketing used the composite selectively; if so, that is a Performance Presentation and Misrepresentation issue. GIPS is a firm-wide claim, not a marketing label for one select product.
3. The analyst's supervisor says: “Just put the safety warning in a footnote and keep the rating; nobody reads footnotes.” How should the analyst respond, and what escalation is appropriate?
Read the worked answer
A footnote does not cure a material omission if the warning is buried or the body of the report still presents the investment case as if the risk does not exist. The analyst should insist that the safety warning be integrated into the investment thesis, with a quantified or bounded scenario: what happens to the $28 DCF if the component is recalled, if approval is delayed, or if the flagship device's sales fall 10–20%? The report should state the rating, the fair value range, and the conditions under which the analyst would change the rating. If the supervisor insists on a misleading presentation, the analyst must escalate to compliance, the research oversight committee, or the firm's senior legal/risk officer.
Escalation should be documented in writing: date, the request, the analyst's objection, and the compliance response. The analyst should not sign off on a report he or she believes is misleading. If the firm retaliates, that is a separate ethics and possibly legal issue. The analyst should also check whether the supplier's warning is public and whether MedTech has disclosed it; if MedTech has not, the analyst can ask management and disclose the unanswered question. The professional standard requires a reasonable basis and full disclosure of material risks, not minimal compliance. The correct response is to protect the integrity of the research product, even at the cost of the IB mandate.